α6β4* nicotinic acetylcholine receptor (nAChR)
(* represents
the possible presence of additional subunits) is mainly distributed
in the central and peripheral nervous system and is associated with
neurological diseases, such as neuropathic pain; however, the ability
to explore its function and distribution is limited due to the lack
of pharmacological tools. As one of the analogs of α-conotoxin
(α-CTx) LvIC from Conus lividus, [D1G, Δ14Q]LvIC (Lv) selectively and potently blocks α6/α3β4
nAChR (α6/α3 represents a chimera). Here, we synthesized
three fluorescent analogs of Lv by connecting fluorescent molecules
6-carboxytetramethylrhodamine succinimidyl ester (6-TAMRA-SE, R),
Cy3 NHS ester (Cy3, C) and BODIPY-FL NHS ester (BDP, B) to the N-terminus
of the peptide and obtained Lv-R, Lv-C, and Lv-B, respectively. The
potency and selectivity of three fluorescent peptides were evaluated
using two-electrode voltage-clamp recording on nAChR subtypes expressed
in Xenopus laevis oocytes, and the
potency and selectivity of Lv-B were almost maintained with the half-maximal
inhibition (IC50) of 64 nM. Then, we explored the stability
of Lv-B in artificial cerebrospinal fluid and stained rat brain slices
with Lv-B. The results indicated that the stability of Lv-B was slightly
improved compared to that of native Lv. Additionally, we detected
the distribution of the α6β4* nAChR subtype in the cerebral
cortex using green fluorescently labeled peptide and fluorescence
microscopy. Our findings not only provide a visualized pharmacological
tool for exploring the distribution of the α6β4* nAChR
subtype in various situ tissues and organs but also extend the application
of α-CTx [D1G, Δ14Q]LvIC to demonstrate the involvement
of α6β4 nAChR function in pathophysiology and pharmacology.